

REMARKS

In the Office Action dated December 24, 2002, claims 1, 7, 8, 15, 19 and 20 in the above-identified U.S. patent application were rejected. Reconsideration of the rejections is respectfully requested in view of the above amendments and the following remarks.

Claims 1 and 7 were rejected under 35 USC §102 as anticipated by or alternatively under 35 USC §103(a) as obvious over Dupont. Claim 1 has been canceled and claim 7 amended to depend from claim 19. Claim 19 has been amended to indicate that the pooled supernatants are lyophilized. As discussed in applicant's prior response, Dupont indicates that lyophilization destroys the activity of his liquid extract. In view of this, applicant's contend that the presently claimed invention is not anticipated or rendered obvious by Dupont and request that this rejection be withdrawn.


Claims 15, 19 and 20 were rejected under 35 USC §102(b) as anticipated by or alternatively under 35 USC §103(a) as obvious over Dupont. Claim 15 has been amended to depend from claim 19 and claim 19 has been amended to more clearly indicate that the pooled supernatants are lyophilized. In view of these amendments, applicants request that this rejection be withdrawn.

Claim 8 was rejected under 35 USC §103(a) as obvious over Halperin and Dupont. Claim 8 has been amended to depend from claim 19 which has been amended to more clearly indicate that the pooled supernatants are lyophilized. In view of these amendments applicants request that this rejection be withdrawn.

Applicants respectfully submit that all of claims 7, 8, 15, 19 and 20 are now in condition for allowance. If it is believed that the application is not in condition for allowance, it is

respectfully requested that the undersigned attorney be contacted at the telephone number below.

In the event this paper is not considered to be timely filed, the Applicant respectfully petitions for an appropriate extension of time. Any fee for such an extension together with any additional fees that may be due with respect to this paper, may be charged to Counsel's Deposit Account No. 02-2135.

RESPECTFULLY SUBMITTED,					
NAME AND REG. NUMBER	Monica Chin Kitts, Registration No.: 36,105				
SIGNATURE				DATE	6/11/03
ADDRESS	Rothwell, Figg, Ernst & Manbeck Suite 800, 1425 K Street, N.W.				
CITY	Washington	STATE	D.C.	ZIP CODE	20005
COUNTRY	U.S.A.	TELEPHONE	202-783- 6040	FAX	202-783- 6031

Enclosures: Marked up copy of claims showing amendments

APPENDIX

Marked-Up copy of claims to show amendments:

7. (Amended) A pharmaceutical composition comprising shark cartilage extract with anti-parathyroid hypertensive factor activity according to claim 19 and a pharmaceutically acceptable carrier.

8. (Amended) A pharmaceutical composition comprising shark cartilage extract with anti-parathyroid hypertensive factor activity according to claim 19, an antihypertensive substance and a pharmaceutically effective carrier.

15. (Amended) The extract according to claim 2 19, wherein said extract is composed of 5-30% protein, 15-80% mucopolysaccharides and 1-20% Chondroitin Sulfate C.

19. (Amended) ~~The A~~ shark cartilage extract with anti-PHF activity ~~according to claim 1~~, wherein the shark cartilage extract is produced by the following steps:

extracting cleaned, dried, ground shark cartilage with H₂O at a temperature between 4-120°C for 2-4 hours,

centrifuging the resulting suspension 1 at between 5200 to 5700 rpm to separate the suspension into supernatant 1 and pellet,

holding the supernatant 1 in a cooling tank at 4-8°C,

extracting the pellet a second time with H₂O at a temperature between 4-120°C for 2-4 hours,

centrifuging the resulting suspension 2 at between 5200-5700 rpm to separate the suspension into supernatant 2 and pellet,

pooling supernatant 1 with supernatant 2, and

~~spray-drying~~ lyophilizing the pooled supernatants to obtain the shark cartilage extract.